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Abstract
Purpose: Nomograms are tools used in clinical practice to predict cancer outcomes and to help make decisions regarding
management of disease. Since its conception,utilityof the prostate cancer nomogram has more than tripled.Limited information
is available on the relation between the nomograms’ predicted probabilities and obesity. The purpose of this study was to
examine whether the predictions from a validated postoperative prostate cancer nomogram were associated with obesity.
Methods: We carried out a cross-sectional analysis of 1220 patients who underwent radical prostatectomy (RP) in southern
California from 2000 to 2008. Progression-free probabilities (PFPs) were ascertained from the 10-year Kattan postoperative
nomogram. Multivariable logistic regression models estimated odds ratios (ORs) and 95% confidence intervals (CIs).
Results: In the present study, aggressive prostate cancer (Gleason $7), but not advanced stage, was associated with obesity
(p=0.01). After adjusting for age, black race, family history of prostate cancer and current smoking, an inverse association
was observed for 10-year progression-free predictions (OR=0.50; 95% CI=0.28–0.90) and positive associations were
observed for preoperative PSA levels (OR=1.23; 95% CI=1.01–1.50) and Gleason .7 (OR=1.45; 95% CI=1.11–1.90).
Conclusion: Obese RP patients were more likely to have lower PFP values than non-obese patients, suggesting a higher risk
of experiencing prostate cancer progression. Identifying men with potentially higher risks due to obesity may improve
disease prognosis and treatment decision-making.
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Introduction
Obesity constitutes a growing public health problem that may
influence the outcome of a number of chronic diseases, including
cancer. In the U.S., the prevalence of obesity has increased
dramatically since 1980, a trend that has been observed across age
and ethnic subgroups. In 2000, approximately 65% of adults were
overweight and 30% were obese [1,2].
Carcinoma of the prostate is the most frequently diagnosed non-
skincancerand the 2
ndleading cause of cancerdeathsinmalesinthe
U.S. In 2009, there were 192,280 incident cases and 27,360
estimated deaths from prostate cancer [3,4]. Several lines of research
suggest that lifestyle factors may be involved in progression of
prostate cancer and development of potentially fatal disease [5,6].
Clinicopathological characteristics determined at time of surgery
(pre-operativeserumPSA)orimmediatelypostoperatively(e.g.stage,
grade, margin status) have constituted a particularly important area
of focus because of their ability to prognosticate recurrence. These
isolated diseasecharacteristics havenotbeenfound to be consistently
associated with body mass across studies [7,8,9,10,11,12]. The
prostate cancer nomogram,a composite measure that incorporates a
group of clinicopathologic characteristics, is used by both clinicians
and patients at the time of diagnosis [13]. Since its conception in
2004, the utility of the prostate cancer nomogram has more than
tripled. Yet, limited information is available on the potential
associations between lifestyle factors, including obesity, with the
nomograms predicted probabilities. Such associations would be
useful in further characterizing high-risk prostate cancer patients
[14]. The purpose of this study was to examine the association of
obesity with the updated 10-year postoperative prostate cancer
nomogram and its individual components.
Materials and Methods
Population
The Strategic Partners for the Evaluation of Cancer Signatures
(SPECS) is an ongoing observational study that uses specimen
tissues and clinical data to derive gene signatures for the prognosis
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study recruitment if they had been diagnosed as having prostate
cancer, scheduled to undergo a radical prostatectomy, and didn’t
have prior radiation or hormonal therapy for prostate cancer. Men
were recruited during the pre-operation clinic visit. Subjects for
the present study consisted of 1298 biopsy-confirmed prostate
cancer patients who underwent prostatectomy between 2000 and
2008 at four centers in southern California. Of the 1298
participants, subjects with missing data for clinicopathologic
factors required for the 10-year postoperative nomogram were
excluded from the analyses (n=78, overlap exists). The final study
population for the present analysis consisted of 1220 subjects.
Signed informed consent was obtained for all participants.
Institutional review board approval for the present study was
obtained from the University of California Irvine, University of
California San Diego, and San Diego State University.
Measures and Procedures
Demographics and anthropometrics were ascertained at the
preoperative clinic visit. Date of birth, race (White, Black, Asian,
Hispanic, Other), current smoking status (yes/no), family history of
prostate cancer (yes/no) were assessed by self-administered
questionnaires. Body mass index (BMI) was calculated by dividing
the patient’s weight in kilograms by their height in meters squared
(kg/m
2). Obesity was defined as BMI $30 according to the WHO
international classification. Pathologic review and reporting was
performed according to standards described by the TNM
classification [15]. Preoperative PSA level was abstracted from
the medical record and pathologic characteristics were obtained
by examination of pathology reports by trained clinical study
coordinators. Surgical margins were categorized as positive or
negative, positive if tumor was present at the inked specimen
surface. Pathological Gleason sum was divided into two groups
according to histology: well differentiated (#6) and poorly
differentiated ($7). Pathological stage was categorized as organ-
confined (T1/T2) or not organ-confined (T3/T4) disease.
Progression-free probabilities (PFP), the probability of avoiding
disease progression, e.g., biochemical recurrence, were derived
using the 10-year postoperative Kattan nomogram (http://www.
mskcc.org/applications/nomograms/Prostate/PostRadicalProsta-
tectomy.aspx). Details of the postoperative Kattan nomogram
have been described [16]. Briefly, the nomogram is a robust
predictive tool which incorporates preoperative PSA level, year of
surgery, Gleason grade (primary and secondary), surgical margins,
pathologic stage and lymph node involvement to predict the 10-
year probability that a prostate cancer will not progress after RP.
The nomogram has been validated in independent samples with
predictive accuracy (Harrell’s concordance index: 0.79 to 0.81;
area under the curve (AUC): 0.89).
Statistical analyses
Descriptive statistics were tabulated for patient characteristics.
Univariate analysis was performed with chi-square tests for
categorical variables and Wilcoxon rank sum for continuous
variables.
Associations of obesity with the 10-year postoperative PFP (and
each of its individual clinicopathologic components) were
performed using multivariable logistic regression. Serial models
were used to assess potential confounding. All models adjusted for
age, given the documented associations of age with both BMI and
prostate cancer. The final model adjusted additionally for black
race, positive family history and current smoking. Odds ratios
(OR) and corresponding 95% confidence intervals (CI) were
calculated. Tests of interaction by age, black race, family history
and current smoking were performed. For analysis, PSA levels
were log-transformed to normalize the data. PFP values were
transformed using the arcsine-square root transformation. After
observing a significant association between obesity and PFP, post
hoc analyses were performed to determine which of the individual
components comprising the PFP index was associated with obesity.
Data were analyzed using SASH (version 9.1, SAS Institute Inc.,
Cary, NC) and Hmisc package in R software (version 2.8). All p-
values were based on two-tailed tests of significance.
Results
The characteristics of the 1220 patients analyzed in the present
study are shown in Table 1. Mean age at time of surgery was 62
years (range 40 to 80) and the study population was predominantly
white, with only 5% of black descent. Twenty-three percent
reported having a family history of prostate cancer. Mean BMI
was 27.7 kg/m
2 (range: 18.3 to 48.8). In our study population, 305
(25%) men were identified with BMI $30 kg/m
2. Preoperative
PSA levels ranged from 0.1 to 78.2 ng/mL with a median value of
5.8 ng/mL (95% CI=4.3–8.5). Fifty-seven percent of the subjects
had a Gleason sum $7 and 10% had values $8. With regards to
tumor stage, the majority (approximately 77%) had disease
confined to the prostate defined as T1/T2; however, 21% had
cancer that had extended beyond the prostatic capsule or into the
seminal vesicles (T3) and 16 men had cancer that spread to the
bladder (T4). About 27% of the subjects who underwent RP had
positive margins. The proportions of subjects with extra-capsular
extension, seminal vesicle invasion and/or positive lymph nodes
were small (19%, 8% and 3%, respectively), consistent with reports
in other RP patient populations.
Unadjusted associations between PFP scores and obesity are
reported in Table 2 along with comparisons for the individual
clinicopathologic characteristics. Gleason sum was strongly
associated with obesity in the univariate analysis (P=0.03),
particularly for Gleason $7 (63% vs. 55%, P=0.01) as was the
predicted progression-free probabilities from the 10-year postop-
erative nomogram (P=0.02). The median values of preoperative
PSA were slightly higher in obese subjects (6.0 vs. 5.7, P=0.05),
albeit not a clinically meaningful difference. The proportion of
subjects with preoperative PSA levels $10 was higher (22% vs.
17%) in obese men compared to non-obese men. Further, a larger
proportion of obese subjects had positive surgical margins (30% vs.
25%); however, these differences were not statistically significant
(P=0.07). No differences were observed between the two groups
for the remaining individual pathological characteristics.
Patients were divided into quartiles based on postoperative
nomogram predicted 10-year PFP (Figure 1). We observed a
significant difference between the obese and non-obese subjects
(P=0.039). A larger proportion of obese subjects had PFP values
in the lower two quartiles (Q1 and Q2). Within the non-obese
men, only marginal differences were shown in the proportion of
subjects within each PFP quartile (range 23.8 to 26.7%). The
difference between obese and non-obese subjects becomes more
apparent when we dichotomize PFP values into two groups, below
and above the median. The proportion of obese subjects who have
PFP values below the median (i.e., a worse prediction) is
significantly higher than the proportion of non-obese subjects
(57.4 vs. 47.9, P,0.01).
Associations between obesity and the 10-year postoperative
nomogram as well as its individual components are reported in
Table 3. In age-adjusted logistic regression analyses, men with a
pathologic Gleason sum $7 were 1.44 times more likely to be
obese than those with a Gleason sum ,7 (OR=1.44, 95%
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of 1.24 for every 1-ng/mL increase in PSA levels. The result for
preoperative PSA was only marginally significant (95%
CI=1.02–1.50). In the fully-adjusted model, these associations
did not change markedly. No associations were found between
obesity and pathologic stage, surgical margins, extra-capsular
extension (ECE), seminal vesicle invasion (SVI) and lymph node
(LN) involvement.
A significant inverse association was observed between obesity
and the PFP nomogram predictions. The odds of being obese
decreases by a factor of 0.87 for every 20% increase in PFP
(OR=0.87, 95% CI=0.77=0.98), after adjusting for age, black
race, family history and current smoking. Based on this finding,
obese RP patients in our study were more likely to have lower PFP
values, suggesting a higher risk of experiencing prostate cancer
progression.
Discussion
In the first study to examine the relation between obesity and
the 10-year postoperative prostate cancer nomogram, our findings
suggest an independent inverse association between obesity and
the probability of remaining progression-free.
Our findings are in accord with those from the one study, to our
knowledge, that examined the association of body mass and
predicted PFP from the 7-year postoperative nomogram [11]. In
this study, researchers examined data from 702 men with a mean
age of 59 years who had undergone RP from 1988 to 2006 and
found that obese patients were predicted on average to have an
absolute decrease in their probability of remaining free of
progression (74.3% vs. 80.1% for obese and non-obese men,
respectively; p=0.04). A limitation noted by the authors is that
they used the 7-year rather than the 10-year Kattan nomogram.
By incorporating year of surgery, the 10-year postoperative
nomogram provides more accurate predictions by taking into
account advances in screening over time [16,17,18]. Because PFP
was not the main focus of their analysis, comparison of PFP values
between obese and non-obese men was performed without
adjusting for potential confounding factors that might have been
important given the reported differences in mean age and year of
surgery between the obese and non-obese men in their study
population. We were able to confirm their findings when using the
10-year nomogram and adjusting for potential confounders.
In two separate cohorts of RP patients with clinically localized
disease, researchers conclude that body mass index (BMI) does not
improve the predictive accuracy of statistical models beyond that
which is already explained by clinicopathologic factors. However,
Table 1. Characteristics of patients undergoing radical
prostatectomy.
Characteristic Men (N=1220)
Age (years), mean (SD) 61.9 (7.0)
Race/ethnicity, n (%)
White 892 (73.1)
Asian 156 (12.8)
Hispanic 63 (5.2)
Black 62 (5.1)
Other 47 (3.8)
Family history of prostate cancer, n (%) 278 (22.8)
Current smoker, n (%) 159 (13.0)
Weight (kg), mean (SD) 87.3 (14.1)
Height (cm), mean (SD) 177.5 (7.8)
BMI (kg/m
2), mean (SD) 27.7 (4.1)
Preoperative PSA, median (95% CI) 5.8 (4.3–8.5)
Pathologic Gleason sum, n (%)
3–6 524 (43.0)
7( 3 +4) 431 (35.3)
7( 4 +3) 139 (11.4)
8–10 126 (10.3)
Pathologic stage, n (%)
T1 7 (0.6)
T2 939 (77.2)
T3 255 (20.9)
T4 16 (1.3)
Positive margins, n (%) 324 (26.6)
Extra-capsular extension, n (%) 232 (19.0)
Seminal vesicle invasion, n (%) 98 (8.0)
Node positive, n (%) 40 (3.3)
BMI, body mass index; PSA, prostate-specific antigen; SD, standard deviation.
doi:10.1371/journal.pone.0017382.t001
Table 2. Clinical and pathologic tumor characteristics
according to obesity.
BMI,30 BMI $30
Characteristic No. % No. % P value
No. of patients 915 305
Preoperative PSA, ng/mL
Median (95% CI) 5.7 (4.2–8.4) 6.0 (4.5–9.2) .05
{
$10 ng/mL 159 17.4 67 22.0 .07
Pathologic Gleason sum .03
3–6 412 45.1 112 36.7
7( 3 +4) 319 34.6 112 36.7
7( 4 +3) 99 11.1 40 13.1
8–10 85 9.2 40 13.4
$7 503 55.0 193 63.3 .01
Pathologic stage .34
T1 5 0.5 2 0.7
T2 710 77.8 229 75.3
T3 189 20.7 66 21.7
T4 9 1.0 7 2.3
T3/T4 198 21.7 73 24.0 .40
Positive margins 231 25.3 93 30.5 .07
Extra-capsular extension 177 19.3 55 18.0 .61
Seminal vesicle invasion 71 7.8 27 8.8 .54
Node positive 30 3.3 10 3.3 .89
10-y Postoperative PFP, %
Mean (SD) 89 (0.2) 87 (0.2) .02
{
BMI, body mass index; PSA, prostate-specific antigen; PFP, progression-free
probability.
P value based on x
2 test unless otherwise indicated.
{Wilcoxon rank sum test;
{Student’s t-test.
doi:10.1371/journal.pone.0017382.t002
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simultaneously and potential confounders, such as age and year
of surgery, were not accounted for in the analyses. Each study
modeled progression within a short period of follow-up (median
follow-up of 25.9 months) [19,20].
Body mass may be linked to lower PFP scores and poorer
disease pathology through a variety of adipose tissue induced-
hormonal changes (e.g., increased levels of insulin and bioavailable
IGF-I that are known to have mitogenic properties). Most
proposed mechanisms point to markers of aggressiveness or extent
of disease spread. Our study suggests evidence to support the
former (e.g., Gleason) but not the latter; we did not observe
associations with extent of disease as measured by pathologic
stage, ECE, SVI, or LN involvement. One possible explanation
may be that TNM stage, unlike Gleason grade, is determined by
both the rate of disease growth (a feature of the degree of
aggressive potential of the disease) and time of detection.
Therefore, observed associations between obesity and stage may
be reflective of the influence of obesity on the timing of detection.
Conversely, Gleason grade is more purely a reflection of the innate
aggressiveness of the disease and is largely unaffected by the timing
of detection. Given this, we might expect that a true biological
effect of obesity on prostate cancer would more likely register as an
association with grade rather than stage.
The present study has both strengths and limitations. A major
strength is the detailed assessment of pathologic tumor character-
istics and objective assessment of weight and height prior to
surgery [21], which is particularly important given that weight
after surgery may not be a good measure due to changes as a result
of disease, treatment, or lifestyle changes. We employed the
updated version of the postoperative nomogram, a validated
prediction tool, which incorporates year of surgery. Additional
strengths include the availability of information that allowed us to
adjust for risk factors that may play a role in prostate cancer
progression such as age, race, family history and cigarette smoking
[3,22,23,24,25,26,27].
Figure 1. Distribution of PFP quartiles by obesity.
doi:10.1371/journal.pone.0017382.g001
Table 3. Adjusted associations between obesity* and RP
patient characteristics.
Model 1 Model 2
Characteristic OR 95% CI OR 95% CI
Black race 1.59 0.90–2.78
Positive family history 0.87 0.64–1.19
Current smoker 0.92 0.62–1.36
Preoperative PSA
{ (ng/mL) 1.24 1.02–1.50 1.23 1.01–1.50
Pathologic Gleason sum, $7 1.44 1.10–1.88 1.45 1.11–1.90
Pathologic stage, T3/T4 1.16 0.86–1.58 1.18 0.86–1.60
Positive margins 1.30 0.98–1.73 1.29 0.97–1.72
Extra-capsular extension 0.93 0.66–1.30 0.94 0.67–1.32
Seminal vesicle invasion 1.19 0.75–1.89 1.20 0.75–1.92
Node positive 0.96 0.45–2.05 0.99 0.48–2.07
10-y postoperative PFP
{
1% increase 0.51 0.28–0.91 0.50 0.28–0.90
20% increase 0.87 0.78–0.98 0.87 0.77–0.98
OR, odds ratio; CI, confidence interval; PFP, progression-free probability.
*Obesity was defined as BMI $30;
{Postoperative PSA was log-transformed;
{PFP was arcsine-transformed.
Model 1: adjusting for age.
Model 2: adjusting for age, black race, family history, current smoker.
doi:10.1371/journal.pone.0017382.t003
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BMI. In addition, other measures of body composition such as
waist-to-hip-ratio were not available to examine the potential
effect of central adiposity. The study population consists of men
undergoing prostatectomy and may not reflect the full range of
BMI that might be seen in the general population. Because the
study population consists of men who underwent RP, the
postoperative nomogram was used; therefore, the observed
associations in the present study may not apply to other prostate
cancer nomograms (e.g., pretreatment nomogram). The present
study was a cross-sectional examination of obesity and tumor
characteristics (and nomogram scores) measured at the time of
surgery and therefore does not establish causality.
In conclusion, findings from the present study suggest that obese
RP patients have a higher risk of experiencing prostate cancer
progression. Identifying men at higher risk for treatment failure
has the potential for better patient treatment decision making and
may aid in the accrual for appropriate clinical trials. However,
results of the present study need confirmation in other study
populations such as large prospective cohorts with adequate length
of follow-up before recommendations regarding treatment can be
made or modifications to the nomogram tool are incorporated.
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